Number of Intermediate- and High-Risk Factors Significantly Predicts Biochemical Survival and Prostate Cancer-Specific Survival After Low-Dose-Rate Brachytherapy

被引:0
|
作者
Shasha, D. [1 ]
Salant, R. [1 ]
Sivathayalan, A. [2 ]
Farrell, P. J. [2 ]
Mourad, W. F. [1 ]
Harrison, L. B. [1 ]
机构
[1] Mt Sinai Beth Israel Med Ctr, New York, NY USA
[2] Carleton Univ, Ottawa, ON K1S 5B6, Canada
关键词
D O I
10.1016/j.ijrobp.2015.07.1172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2617
引用
收藏
页码:E248 / E249
页数:2
相关论文
共 50 条
  • [21] Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer
    Gestaut, Matthew M.
    Cai, Wendi
    Vyas, Shilpa
    Patel, Belur J.
    Hasan, Salman A.
    MunozMaldonado, Yolanda
    Deb, Niloyjyoti
    Swanson, Gregory
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 101 - 107
  • [22] Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer
    Uematsu, Toshitaka
    Torimoto, Kazumasa
    Tanaka, Nobumichi
    Asakawa, Isao
    Hori, Shunta
    Yamaki, Kaori
    Nakai, Yasushi
    Miyake, Makito
    Anai, Satoshi
    Hasegawa, Masatoshi
    Fujimoto, Kiyohide
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2022, 14 (01) : 4 - 9
  • [23] Early and Late Complications after High Dose Rate Brachytherapy of Intermediate and High-Risk Prostate Cancer
    Ulys, A.
    Burneckis, A.
    Aleknavicius, E.
    Vezelis, A.
    Kasulaityte, L.
    UROLOGY, 2012, 80 (03) : S303 - S303
  • [24] Low-Dose-Rate Brachytherapy as Monotherapy for High-Risk Prostate Cancer: 15-Year Outcomes Data
    Lazarev, Stanislav
    Liu, Jerry
    Thompson, Marcher
    Ghiassi, Zahra
    Stone, Nelson N.
    Stock, Richard G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E8 - E9
  • [25] Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
    Boehle, Andreas
    Zywietz, Dorothea
    Robrahn-Nitschke, Irina
    Koenig, Inke R.
    Lusch, Achim
    ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (02)
  • [26] Biologically effective dose (BED) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer
    Miles, E. F.
    Nelson, J. W.
    Alkaissi, A. K.
    Das, S.
    Clough, R. W.
    Anscher, M. S.
    Oleson, J. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S319 - S319
  • [27] Dosimetry and cancer control after low-dose-rate prostate brachytherapy
    Lee, WR
    DeGuzman, AF
    McMullen, KP
    McCullough, DL
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (01): : 52 - 59
  • [28] Prostate-specific antigen (PSA) kinetics following focal low-dose-rate (LDR) brachytherapy for intermediate risk prostate cancer
    Harkin, Timothy
    Smyth, Lloyd
    Anderson, Elliot
    O'Sullivan, Richard
    Ryan, Andrew
    Lawrentschuk, Nathan
    Katz, Darren
    Grummet, Jeremy
    See, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 91 - 91
  • [29] Outcomes of High-Dose Rate (HDR) Brachytherapy in Intermediate- to High-Risk Prostate Cancer Patients with Prior Transurethral Resection of the Prostate (TURP)
    Lin, E. Y.
    Lee, A.
    Demanes, J.
    Kamrava, M.
    Venkat, P. S.
    Hagio, M. A.
    Zaide, L. B.
    Park, S. J.
    Zarate, C.
    Chang, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E888 - E888
  • [30] THE NUMBER OF POSITIVE SECTION MARGINS IN HIGH-RISK PROSTATE CANCER IS A POWERFUL AND INDEPENDENT PREDICTOR OF CANCER-SPECIFIC AND OVERALL SURVIVAL IN HIGH-RISK LOCALIZED PROSTATE CANCER
    Joniau, Steven
    Gontero, Paolo
    Briganti, Alberto
    Marchioro, Giansilvio
    Capitanio, Umberto
    Bader, Pia
    Tombal, Bertrand
    Frea, Bruno
    Tizzani, Alessandro
    Riedmiller, Hubertus
    Van Poppel, Hein
    Spahn, Martin
    JOURNAL OF UROLOGY, 2011, 185 (04): : E191 - E191